|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.26 USD | +5.71% |
|
+7.22% | +58.62% |
| Mar. 06 | Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) | RE |
| Mar. 03 | Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran | CI |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Neutral | Neutral |
| Resistance | 15.44 | 27.98 | 25.6 |
| Spread/Res. | -7.64% | -49.04% | -44.30% |
| Spread/Supp. | +22.40% | +77.36% | +107.57% |
| Support | 11.65 | 8.04 | 6.87 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Equities
- NTLA Stock
- Charts Intellia Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
